ClinicalTrials.gg
RecruitingNCT07281599EQUIPUpdated Jul 24, 2026

Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer

An interventional study of Q-Pad hrHPV Test System in HPV Infection, HPV 16 Infection and High Risk HPV, sponsored by Qurasense. Recruiting at 3 sites in United States. Open to female participants aged 25 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Qurasense · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Not applicable
Ages
25 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 166 studies in Papillomavirus Infections with a site in United States — 32 open to participants now, 60 under way, 5 of them phase 3. Papillomavirus Infections · United States.

Planned enrollment
40th of 132
450 · median 128
Started
2025
with 9 others
No phase
53 of 166
14 open now
Primary completion
2026-12
later than 18 of 59 live
Registered
159th of 166
by date

Among the 166 studies in Papillomavirus Infections with a site in United States, this one is the 40th largest by planned enrollment of the 132 interventional ones that give a count, is one of 10 that started in 2025, is one of 53 with no phase, reaches primary completion later than 18 of the 59 other live ones, and was the 159th registered.

Papillomavirus Infections

581 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

32 of the 166 studies in Papillomavirus Infections with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Papillomavirus Infections studies recruiting now, 40 (45%) set no upper age limit and 44 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 25 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Papillomavirus Infections with a site in United States, or all of them as a file.
02

Study summary

The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing.

The same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care. By comparing hrHPV results from menstrual samples with results from cervical samples and biopsy findings, the study will evaluate how well the Q-Pad hrHPV Test System detects cervical precancer and will also assess how easy and acceptable it is for participants to use this at-home collection method.

Read the detailed description

The EQUIP Study is a prospective, multicenter method-comparison study designed to evaluate the diagnostic performance of the Q-Pad hrHPV Test System for cervical cancer screening. Menstruating adults referred for colposcopy after an abnormal cervical screening result receive a mailed Q-Pad Kit and use it during the menstrual cycle immediately after their clinic visit to collect a menstrual samples at home, guided by written instructions and an optional accompanying smartphone application. These samples are returned by mail to a central laboratory, where hrHPV testing is performed using a PCR assay.

At the colposcopy visit, clinicians obtain a standard cervical specimen for routine cytology and hrHPV testing on the same assay platform and perform colposcopy with biopsy as clinically indicated. Each participant therefore provides both an at-home menstrual sample (index test) and a clinician-collected cervical sample (comparator) within the same episode of care, with biopsy and histopathology providing disease status. The study focuses on comparing hrHPV results between the two specimen types and on evaluating safety, specimen adequacy, and participant usability and acceptability of the Q-Pad at-home menstrual collection approach.

03

Conditions studied

  • HPV Infection
  • HPV 16 Infection
  • High Risk HPV
  • Cervical Cancer Screening
  • Cervical Cancer Cin Grade
  • Cervical Cancer (Early Detection)
  • HPV
  • HPV (Human Papillomavirus)-Associated
  • HPV DNA
  • HPV Infections
  • Screening Test

Keywords

  • Q-Pad
  • Self-sampling
  • Self-collection
  • self-collect
  • cervical cancer screening
  • menstural blood
  • Sexually Transmitted Diseases, Viral
  • Sexually Transmitted Diseases
  • Genital Diseases
  • Papillomavirus Infections
  • HPV
  • high risk HPV
  • pap smear
  • at-home collection
04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • You are 25 years old or older and have an intact cervix.
  • You were referred for a colposcopy after an abnormal Pap or HPV screen.
  • Your periods come regularly-about every 21-35 days.
  • You own a smartphone, have an email address, and can read the Qvin app instructions in English.
  • You are willing to sign the consent form (electronically).
  • You agree to use a condom for any vaginal intercourse or shared penetrative toy use from Q-Pad collection until the colposcopy visit if engaging with a new sexual partner during this period.

Exclusion criteria

Exclusion Criteria:

  • You are pregnant or think you might be.
  • You are unwilling or unable to use the two Q-Pads and mail them back (mailing costs are covered).
  • You had treatment for cervical pre-cancer (CIN2+)-such as LEEP, cone, or ablation-within the last 12 months.
  • You have already joined this study or are in another cervical-screening / HPV study right now.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Other
    Non-invasive, passive self-collection / Clinician collection

    Participants referred for colposcopy after abnormal cervical screening will collect menstrual blood at home using the Q-Pad kit and mail the sample for hrHPV testing. At the colposcopy visit, they will have a clinician-collected cervical specimen obtained for hrHPV testing and undergo colposcopy with biopsy as part of standard care.

    Device: Q-Pad hrHPV Test System

Interventions

  • DeviceQ-Pad hrHPV Test System

    Participants will receive a mailed Q-Pad Kit, which includes two Q-Pads (menstrual pads with removable collection strips called Q-Strips), a Q-Strip Container with desiccant for storing and shipping the strips, and a prepaid return mailer. During the menstrual cycle after their colposcopy visit, participants will follow the Instructions for Use to passively collect menstrual blood with the Q-Pads, then remove the Q-Strips and place them in the Q-Strip Container for mailing to the central laboratory for hrHPV testing. At the colposcopy visit, the clinician will also collect a cervical sample in ThinPrep liquid-based cytology medium for hrHPV testing, which will serve as the comparator specimen.

    Also known as: Q-Pad Kit, Colposcopy, Clinician collection

06

What researchers measure

Primary outcomes

  1. Clinical Performance vs Histology

    Clinical sensitivity defined as the proportion of participants with biopsy-confirmed CIN2+ whose menstrual-blood hrHPV result (Q-Pad hrHPV Test System) is positive and Clinical specificity defined as the proportion of participants with \<CIN2 on histology whose menstrual-blood hrHPV result is negative.

    Time frame: Through study completion, an average of 1 year.

  2. Proportion of participants with at least one reportable device-related adverse event (ADE or SADE)

    Proportion of participants who experience at least one adverse event or device deficiency that is not on the protocol's non-reportable event list.

    Time frame: Through study completion, an average of 1 year.

Secondary outcomes

  1. Positive, negative, and overall percent agreement between Q-Pad hrHPV testing and clinician-collected cervical hrHPV testing

    Positive percent agreement (PPA), negative percent agreement (NPA), and overall percent agreement (concordance) between the Q-Pad hrHPV Test System result on menstrual blood (index test) and the hrHPV result from the paired clinician-collected cervical ThinPrep specimen (comparator test).

    Time frame: Through study completion, an average of 1 year.

  2. Q-Pad hrHPV Test System validity rate and participant usability/acceptability

    Proportion of returned Q-Pad menstrual collections that yield a valid hrHPV test result in the central laboratory (i.e., not invalid or quantity-not-sufficient \[QNS\]), together with participant usability and acceptability scores for the Q-Pad kit.

    Time frame: Through study completion, an average of 1 year.

Other outcomes

  1. CIN3+ Clinical Sensitivity & Specificity

    Using biopsy as reference, calculate clinical sensitivity/specificity of Q-Pad hrHPV for detecting CIN3+ lesions

    Time frame: Through study completion, an average of 1 year.

07

Study locations

3 of 3 sites recruiting
  • Planned Parenthood of Southern New England
    New Haven, Connecticut 06511, United States
    Recruiting
  • Planned Parenthood North Central States
    Minneapolis, Minnesota 55408, United States
    Recruiting
  • Planned Parenthood of Greater Ohio (PPGOH)
    Akron, Ohio 44302, United States
    Recruiting
08

References and documents

Publications

  • Arbyn M, Peeters E, Benoy I, Vanden Broeck D, Bogers J, De Sutter P, Donders G, Tjalma W, Weyers S, Cuschieri K, Poljak M, Bonde J, Cocuzza C, Zhao FH, Van Keer S, Vorsters A. VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples. J Clin Virol. 2018 Oct;107:52-56. doi: 10.1016/j.jcv.2018.08.006. Epub 2018 Aug 22. PubMed 30195193 ↗
  • Naseri S, Young S, Cruz G, Blumenthal PD. Screening for High-Risk Human Papillomavirus Using Passive, Self-Collected Menstrual Blood. Obstet Gynecol. 2022 Sep 1;140(3):470-476. doi: 10.1097/AOG.0000000000004904. Epub 2022 Aug 3. PubMed 35926207 ↗
  • U.S. Food and Drug Administration, "510(k) Substantial Equivalence Determination Decision Summary: Q-Pad A1c Test System (K231465)," 2023, accessed June 11, 2025, https://www.accessdata.fda.gov/cdrh_docs/pdf23/K231465.pdf.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 119 interventional studies with no phase under Papillomavirus Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Dec 15, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 2027
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07281599
Lead sponsor
Qurasense
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Dec 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jul 24, 2026

Study contacts

Brian Weinberg, MS
Contact
care@qvin.com
833-367-7846
Paul Blumenthal, MD, MPH
study director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion